Navidea asks investors for some patience; Allergan wins FDA nod for aesthetic implant;

@FierceMedDev: Siemens skirts whistleblower suit over alleged Chinese kickbacks. News | Follow @FierceMedDev

> Navidea's ($NAVB) stock has dropped almost 25% since it raised $30 million in a public offering last month, and now the company is entreating investors to cut it some slack. More

> The FDA said it will complete the phase-out of all inhaler devices containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. Item

> Massachusetts General Hospital researchers have come up with a way to deliver a light signal to specific tissues deep inside the body, an advance that should help propel light-activated therapy in the future. Item

> Allergan ($AGN) won FDA approval for Juvéderm Voluma XC, an aesthetic implant designed to correct volume loss in the cheek area. News

> Bioject Medical Technologies of Oregon will use Singapore's Fondaco PTE to distribute needle-free injection devices in Singapore, Indonesia and Malaysia. Item

> Gore landed number 5 on the list of the World's Best Multinational Workplaces, an annual ranking of the 25 best multinational companies in terms of workplace culture. Item

Biotech News

@FierceBiotech: New feature: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Problem with Lilly: even if they get new diabetes drugs approved--everyone is piling into the same niches. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Ariad's Iclusig agony has put a hold on its planned move to Cambridge's biotech hotbed. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: This week's issue of FierceBiotech Research is out. Check it out | Follow @EmilyMFierce

> Alzheimer's team tackles a daunting R&D field with a new game plan. News

> Is Roche going to do some big rare disease drug deals? More

> FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir. Story

> Merck's beleaguered R&D division wins its second 'breakthrough' title at FDA. Article

Pharma News

@FiercePharma: Tuesday's top news: Astellas + Medivation prostate-cancer prodigy Xtandi shines in pre-chemo. Article | Follow @FiercePharma

@EricPFierce: Amarin cuts 50% of its staff after FDA panel vote leaves Vascepa extension high and dry. News | Follow @EricPFierce

@CarlyHFierce: Reckitt Benckiser weighs pharma-unit sale as Suboxone slumps. More | Follow @CarlyHFierce

> Lilly diabetes drugs, price hikes fuel 6% sales boost. News

> GlaxoSmithKline bribery probe takes 61% bite out of China sales. More

> Amgen earnings jump amid Onyx buyout, Asia deal. Story

Drug Delivery News

@MichaelGFierce: New method allows first-ever delivery of highly toxic cancer drug. More | Follow @MichaelGFierce

> Molecular 'grenades' from GenSpera reel in PhI liver cancer success. Story

> Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery. Article

> Study: Heated chemo-delivering nanoparticles kill 95% of ovarian cancer cells. Report

> Implantable, light-sensitive hydrogel could help treat diabetes. Item

Diagnostics News

@MarkHFierce: The top med tech VC investments of Q3 are all late-stage companies. Click for all the juicy details. FierceMedicalDevices feature | Follow @MarkHFierce

> Myriad targets 3rd company with BRCA cancer test lawsuit. News

> King's College London team make strides toward rapid sepsis test. More

> QuantuMDx gets $1.6M government grant for superfast, portable TB test. Story

> Precipio grabs $1.7M to grow cancer Dx services business with Yale connection. Article

> Roche to close 454 Life Sciences as it reduces gene sequencing focus. Report

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.